HOPE From the Cerebellum: TMS-Induced Cognitive Recovery After Stroke

NCT06316557 · tracked via the Priya Life Science China tracker

Sponsor

Zi-Xiao Li

Phase

Not applicable

Started

2025-01-01

Last updated

2025-07-02

Condition(s) studied

Post-stroke Cognitive ImpairmentIschemic Stroke

Investigational drug(s) / intervention(s)

iTBS groupcontrol group

iTBS group: iTBS on the contralesional cerebellum, twice a day for seven days

control group: shame stimulation on the contralesional cerebellum, twice a day for seven days

Study summary

The objective of this clinical trial is to investigate the effectiveness and safety of repetitive transcranial magnetic stimulation (rTMS) in the cerebellum for individuals with post-stroke cognitive impairment. Participants will undergo rTMS in the cerebellar hemisphere opposite the lesion site, once daily for a total of five days.

Eligibility

Sex

ALL

Min age

18 Years

Max age

—

Healthy volunteers

Key inclusion criteria: (1)ischemic stroke, with an initial incident occurring within 2 weeks;(2)MoCA\<26; Key exclusion criteria: (1)Cerebral hemorrhage or subarachnoid hemorrhage;(2)A pre-existing history of epilepsy;

Primary outcome measure(s)

The efficacy of improving cognitive function of post-stroke cognitive impairment — 3 months follow-up after treatment
The change of MoCA between baseline and 3 months follow-up

Trial sites (1)

Facility	City	Region	Status
Beijing Tiantan hospital	Beijing	China	Recruiting

Other trials for the same condition

Change in Serum Biomarkers After Endovascular Treatment for Acute Anterior Circulation Large Vessel Occlusion Recruiting

Antithrombotic Drug Use in Patients With Ischemic Stroke and Microbleeds Recruiting

Repeated Intravenous Thrombolysis for Ischemic Stroke Within 3.0 Hours of Onset With Tenecteplase (RITIS-TNK) Recruiting

Effects of Short-term Intensive Statin Therapy on Lipid Levels Recruiting

Tenecteplase Plus Urinary Kallidinogenase for Acute Ischemic Stroke (TUKIS) Recruiting

Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT06316557 on ClinicalTrials.gov ↗ ← All trials in China